Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Corbus Pharmaceuticals Holding is a biotechnology business based in the US. Corbus Pharmaceuticals Holding shares (CRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Corbus Pharmaceuticals Holding employs 41 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.26 |
|---|---|
| 52-week range | $0.21 - $1.79 |
| 50-day moving average | $0.30 |
| 200-day moving average | $0.59 |
| Wall St. target price | $1.98 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.31 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.258 from 2022-07-01
| 1 week (2022-06-28) | -4.44% |
|---|---|
| 1 month (2022-06-06) | -13.13% |
| 3 months (2022-04-06) | -41.50% |
| 6 months (2022-01-06) | -53.51% |
| 1 year (2021-07-06) | -84.73% |
|---|---|
| 2 years (2020-07-06) | -96.74% |
| 3 years (2019-07-05) | 6.84 |
| 5 years (2017-07-05) | 6.3 |
| Revenue TTM | $233,881 |
|---|---|
| Gross profit TTM | $-35,563,580 |
| Return on assets TTM | -26.02% |
| Return on equity TTM | -51.11% |
| Profit margin | 0% |
| Book value | $0.49 |
| Market capitalisation | $31.6 million |
TTM: trailing 12 months
We're not expecting Corbus Pharmaceuticals Holding to pay a dividend over the next 12 months.
Over the last 12 months, Corbus Pharmaceuticals Holding's shares have ranged in value from as little as $0.208 up to $1.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corbus Pharmaceuticals Holding's is 2.0268. This would suggest that Corbus Pharmaceuticals Holding's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Corbus Pharmaceuticals Holdings, Inc. , a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
